The transfer of sponsor tasks is the documented handover of trial-related activities from the sponsor to a service provider. It defines who operationally performs a task, but leaves the sponsor’s ultimate responsibility for participant protection and the reliability of trial data unaffected.<\/p>\n
Under ICH E6(R3), sponsor agreements with investigators, institutions, service providers, and other involved parties must be documented before the respective activity begins. When sponsor tasks are transferred to and assumed by a service provider, their specific description belongs in the agreement. Substantial changes to the transferred activities should be tracked. This creates a verifiable framework for which service, which interfaces, which data, and which escalation pathways have been agreed.<\/p>\n
The principle is simple but practically significant: what has not been expressly transferred and assumed remains with the sponsor. A general service description or the label “Full Service” is therefore not sufficient as a substitute for a clear task allocation. For safety reports, data management, monitoring, logistics, or archiving, the agreement should make clear the responsibility, access rights, communication pathways, documentation, and handling of deviations.<\/p>\n
Under the Regulation, the sponsor may in principle delegate individual or all sponsor tasks in writing to a person, company, institution, or organisation. The transfer does not, however, alter its regulatory ultimate responsibility. ICH E6(R3) expressly names the protection of the rights, safety, and well-being of participants as well as the reliability of trial data. The service provider must operate appropriate quality management and report relevant incidents to the sponsor.<\/p>\n
The transfer must also not shift investigator responsibilities unnoticed. If the sponsor appoints a service provider for activities that are performed under the investigator’s responsibility, the investigator must be informed. For these activities, the investigator remains responsible. The contractual design must therefore distinguish between sponsor tasks, support services for the trial site, and the investigator’s medical responsibility.<\/p>\n
The transfer describes the mechanics of performance: which task is handed over to whom and assumed by agreement? Sponsor oversight, by contrast, describes the sponsor’s ongoing obligation to assess the suitability and performance of investigators and service providers, escalate problems in a timely manner, and follow up. A signed contract does not end the task but rather creates the basis on which oversight can verify whether the service is functioning as intended.<\/p>\n
Both concepts therefore have different documents and questions. For transfer, the task matrix, service description, and contract amendment are central. For oversight, risk-adequate control measures, metrics, reports, findings, and their follow-up are decisive. The sponsor remains responsible for its trial-related tasks; here this principle is understood as the limit of transfer, while in the neighbouring entry sponsor-oversight it is understood as the reason for ongoing control.<\/p>\n
The agreement must also consider the lifecycle of a service. Before commencement, qualification and release are required; during the trial, performance monitoring, changes, and escalations are regulated; at completion, return or retention of documents and secure data access follow. When documents or data holdings are transferred, it must be defined who retains originals, certified copies, and metadata. The transfer thus remains traceable even when a service provider changes or ends its activity.<\/p>\n
A task matrix alone is not sufficient if it does not match the actual system permissions and workflows. Responsibilities for review, release, and escalation should therefore also be tested in practice.<\/p>\n
Unclear transfers frequently lead to operational gaps in trials, for example when no one assesses safety information within the required timeframe, controls system access, or decides on central data queries. Interfaces to subcontractors are particularly prone to disruption. A robust agreement links tasks, quality requirements, data access, notifications, retention, and audit or inspection access. It also enables the trial site to identify whom to contact for technical or safety-related questions.<\/p>\n
Full-service CROs such as Mediconomics support the preparation of service descriptions and responsibility matrices, the coordination of safety and data flows, the documentation of contract amendments, and the coordination of involved specialist providers. They can structure the required documents in the Trial Master File, map subcontractor interfaces, and make the implementation of transferred activities traceable together with project management, monitoring, and quality management.<\/p>\n
Must every transferred task be described in writing?<\/strong><\/p>\n Yes. ICH E6(R3) requires documentation in an agreement for transferred sponsor tasks assumed by the service provider. Tasks not specifically transferred remain with the sponsor.<\/p>\n Can a sponsor transfer all operational tasks?<\/strong><\/p>\n The Regulation permits in principle the transfer of individual or all tasks. This does not eliminate the sponsor’s responsibility for compliant conduct, participant protection, and data reliability.<\/p>\n Is the transfer identical to the delegation log at the trial site?<\/strong><\/p>\n No. The transfer concerns sponsor and service provider. The delegation log or delegation record documents the activities delegated by the investigator to persons at the trial site.<\/p>\n The transfer of sponsor tasks is the documented handover of trial-related activities from the sponsor to a service provider. It defines who operationally performs a task, but leaves the sponsor’s ultimate responsibility for participant protection and the reliability of trial data unaffected. Mechanics of Transfer Under ICH E6(R3), sponsor agreements with investigators, institutions, service providers, […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[21],"class_list":["post-8066","glossary","type-glossary","status-publish","hentry","glossary-cat-clinical-operations-gcp"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8066\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8066"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n